NVO Novo Nordisk A/S
49.78
+0.12 (+0%)
Previous Close
49.66
Open
49.82
Price To Book
15.13
Market Cap
119065806849
Shares
2,391,840,234
Volume
660,060
Short Ratio
3.02
Av. Daily Volume
1,596,459
NewsSee all news
- Pharma Stock Roundup: MRK Buys IMDZ, FDA Grants Priority Review to Some Candidates
- Should You Invest in the VanEck Vectors Pharmaceutical ETF (PPH)?
- Novo Nordisk Gets FDA Nod for Haemophilia Drug Esperoct
- Seattle Genetics' Adcetris Gets EC Nod for Label Expansion
- Market Trends Toward New Normal in GameStop, Novo Nordisk A/S, Ferroglobe, PC Connection, Nanometrics, and Anavex Life Sciences — Emerging Consolidated Expectations, Analyst Ratings
SEC filingsSee all SEC filings
- 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] 19623965
- 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] 19616989
- 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] 19613521
- 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] 19600698
- 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] 19587483
Drug Information
Drug catalyst information is displayed when you hover over the stage bar graph.
Approval announced August 25, 2017.
Victoza (liraglutide)
Type 2 diabetes
Approved September 29, 2017.
Fiasp (fast-acting insulin aspart)
Type 1 and type 2 diabetes
Phase 3 trial to be initiated 2Q 2019.
Somapacitan
Growth Hormone Deficiency (GHD)
Approval announced December 5, 2017.
Semaglutide
Type 2 diabetes
Approval announced May 31, 2017.
Nonacog beta pegol
haemophilia B
FDA Approval announced February 19, 2019.
N8-GP
Hemophilia A
Phase 2 trial to commence 1Q 2019.
AM833
Obesity
Latest News
- Pharma Stock Roundup: MRK Buys IMDZ, FDA Grants Priority Review to Some Candidates
- Should You Invest in the VanEck Vectors Pharmaceutical ETF (PPH)?
- Novo Nordisk Gets FDA Nod for Haemophilia Drug Esperoct
- Seattle Genetics' Adcetris Gets EC Nod for Label Expansion
- Market Trends Toward New Normal in GameStop, Novo Nordisk A/S, Ferroglobe, PC Connection, Nanometrics, and Anavex Life Sciences — Emerging Consolidated Expectations, Analyst Ratings
- Sanofi (SNY) Q4 Earnings Top, Genzyme Unit Drives Sales Growth
- Novo Nordisk Is on the Upswing -- for Now
- Sanofi's Myeloma Candidate Meets Goal in Phase III Study
- Merck's Keytruda Clinches CHMP Nod for Difficult Lung Cancer
- Novo Nordisk (NVO) Q4 2018 Earnings Conference Call Transcript
- Attention Biotech Investors: Mark Your Calendar For These February PDUFA Dates
- [$$] Danish Drugmaker Expects Higher Working Capital as Brexit Looms
- Novo Nordisk (NVO) Q4 Earnings Miss Estimates, Revenues Beat
- Novo Nordisk CEO backs ending drug industry rebate system
- Novo Nordisk: 4Q Earnings Snapshot
- Novo Nordisk's new diabetes drug, outlook lift shares
- Novo Nordisk CEO Applauds Trump Plan to Limit Rebates
- [$$] Novo Nordisk Net Profit Rise Misses Expectations
SEC Filings
- 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] 19623965
- 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] 19616989
- 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] 19613521
- 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] 19600698
- 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] 19587483
- SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 19571182
- 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] 19566140
- IRANNOTICE - Notice of disclosure filed pursuant to Section 219 of the Iran Threat Reduction and Syria Human Rights Act of 2012 (Exchange Act Section 13(r)). 19562983
- 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)] 19562947
- 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] 19562843